| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5661526 | Pancreatology | 2017 | 7 Pages |
Abstract
Incretin-based therapy is not associated with acute pancreatitis and short-term pancreatic cancer risk among ethnic Chinese patients with diabetes. This study supports the pancreatic safety of incretin-based pharmacotherapy.
Keywords
FDAIncretin-based therapiesLHIDAERSDPP4GLP-1NHIRDHbA1cGlucagon-like peptide-1 receptor agonistsICDDiabetes mellitusFood and Drug AdministrationPancreatic cancerAdverse Event Reporting SystemInternational Classification of Diseaseconfidence intervalDipeptidyl peptidase-4 inhibitorshazard ratioodds ratioHemoglobin A1cAcute pancreatitisLongitudinal Health Insurance DatabaseNational Health Insurance Research Databaseglucagon-like peptide-1
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Chao-Ming Tseng, Wei-Chih Liao, Chi-Yang Chang, Ching-Tai Lee, Cheng-Hao Tseng, Yao-Chun Hsu, Jaw-Town Lin,